FIGURE

Fig. 1

ID

ZDB-FIG-240305-5

Publication

Zorman et al., 2023 - The overview of development of novel bacterial topoisomerase inhibitors effective against multidrug-resistant bacteria in an academic environment: from early hits to in vivo active antibacterials

Other Figures

All Figure Page

Back to All Figure Page

Fig. 1

Crystal structure of an NBTI representative (AMK12; compound 1) developed in our laboratories in ternary complex with the Staphylococcus aureus DNA gyrase and oligonucleotide (PDB ID: 6Z1A) (Reck et al., 2012). For clarity purpose, two ciprofloxacin molecules were inserted artificially, indicating the difference in binding sites between fluoroquinolones and NBTIs. The protein is shown as a light blue ribbon, the oligonucleotide as a beige ribbon, while the NBTI (hot pink) and fluoroquinolones (yellow) are portrayed in stick representation and color coded by element. The symmetrical bifurcated halogen bonds are represented as orange dashes. On the right: the main structural features of the NBTI molecule (compound 1); the “left-hand side” (LHS) and the “right-hand side” (RHS) connected by the linker. Our design strategy includes a simple phenyl RHS, substituted in such a manner to allow symmetrical bifurcated halogen-bonding with the backbone carbonyl oxygens of both Ala68 residues.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Eur. J. Pharm. Sci.